We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary TESARO to Participate in Several Upcoming Investor Conferences
WALTHAM, Mass., Aug. 30, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, announced that Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President of TESARO, will participate in several upcoming investor conferences during the month of
View HTML
Toggle Summary TESARO Announces Second-Quarter 2013 Operating Results
Top-Line Results from Rolapitant Phase 3 Program to be Announced by Year-End 2013 Patient Enrollment Ongoing in Phase 3 Trial of Niraparib in Ovarian Cancer Phase 3 Trial of Niraparib in Breast Cancer On Track to Begin 2H 2013 First TSR-011 Clinical Data Accepted for Presentation at ESMO Cash and
View HTML
Toggle Summary TESARO Initiates Phase 3 Trial of Niraparib for Treatment of Patients With Ovarian Cancer
First Patient Enrolled in the NOVA Study
View HTML
Toggle Summary TESARO to Announce Second Quarter 2013 Financial Results on July 25, 2013
WALTHAM, Mass., July 18, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its second quarter 2013 financial results on Thursday, July 25, 2013, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast on Thursday,
View HTML
Toggle Summary TESARO to Present at the 8th Annual JMP Securities Healthcare Conference
WALTHAM, Mass., July 2, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, will present at the 8 th Annual JMP Securities 2013 Healthcare Conference at The St. Regis Hotel in New York City on Tuesday, July 9, 2013 at 1:30 p.m. EDT.
View HTML
Toggle Summary TESARO Announces Presentation of Rolapitant Pharmacokinetic (PK) Data at the MASCC/ISOO International Symposium
PK Data from Drug-Drug Interaction Study Describes Lack of CYP3A4 Interactions BERLIN, June 28, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that results from a pharmacokinetic study of rolapitant, an NK-1 receptor antagonist,
View HTML
Toggle Summary TESARO Details Niraparib Phase 1 Clinical Data Presented at the 2013 ASCO Annual Meeting
A RECIST Response Rate of 75% Was Achieved at the 300mg Dose in Patients With Platinum-Sensitive High Grade Serous Ovarian Cancer A RECIST Response Rate of 50% Was Achieved Across All Dose Levels in Patients With Platinum Sensitive Ovarian Cancer and Germline BRCA Mutations Progression Free
View HTML
Toggle Summary TESARO and the European Network of Gynecological Oncological Trial Groups (ENGOT) Forge Partnership to Develop Niraparib for Ovarian Cancer
CHICAGO, June 3, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, and the European Network of Gynecological Oncological Trial Groups (ENGOT), a network of national and regional clinical trial organizations, today announced a partnership for the
View HTML
Toggle Summary TESARO, Breast International Group (BIG), and the European Organization for Research and Treatment of Cancer (EORTC) Announce Collaboration for Niraparib Clinical Development in Breast Cancer
CHICAGO and BRUSSELS, Belgium, June 3, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, Breast International Group (BIG), a non-profit organization for academic breast cancer research groups from around the world, and the European Organization for
View HTML
Toggle Summary TESARO to Webcast Investor Briefing at ASCO
WALTHAM, Mass., May 28, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) invites investors and the general public to listen to a webcast of a presentation by the TESARO management team at an investor briefing on Sunday, June 2, 2013 at 6:15 p.m. Central time, in connection with the annual
View HTML